To evaluate the anti-tumor activity of the two combinations (VS4718 with LXS196 or Trametinib) identified in UM cell lines, we selected three UM PDX models (MM309, MM339, and MM26) obtained from UM metastatic samples displaying GNAQ/11 activating mutations and either BAP1 deficiency (MM309, MM339) or a SF3B1 mutation (MM26). The gene discussed is BAP1; the disease is neoplasm.